This HCP guide is a condition of the Marketing Authorisation for Enhertu. It serves to minimise the important potential risk of medication error in addition to the SmPC. HCPs should read it before prescribing and administering Enhertu (trastuzumab deruxtecan). Risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products including Kadcyla (trastuzumab emtansine).

This HCP guide is: - provided for HCPs to read before prescribing and administering Enhertu - an important tool to ensure the early recognition and diagnosis of ILD/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes - a reminder to distribute a Patient Card to any patient receiving Enhertu treatment for the first time or if asked for a new copy

- This Patient Card has been provided to you because your doctor has prescribed you Enhertu. - This Patient Card helps you to identify symptoms of lung problems that you may experience with Enhertu. - Read this information before you start receiving Enhertu and before each infusion. - You should keep this card with you at all times and show it to any doctor you consult (for example if your regular doctor is unavailable or if you are travelling).